Immunotherapy in the treatment of lymphoma

Table 1 Monoclonal antibody studies

Drug [Ref.]	Target	No. of patients	Study design	Study phase	Results
Obinutuzumab	CD20
[42]		781	CLL (CIRS ≥ 6) O + Clb vs R + Clb	3	PFS: 28.9 mo vs 15.7 mo (HR 0.49, P < 0.0001; OS: NR vs 73.1 mo (HR 0.76, P = 0.0245) Grade ≥ 3 AEs: Infusion reactions 20% vs 4%, Neutropenia 33% vs 28%
[44]		1202	FL (untreated) O + Chemo vs R + Chemo	3	3-yr PFS rate: 80.0% vs 73.3% HR 0.66 P = 0.001 ORR: 88.5% vs 86.9% 3-yr OS rate: 94.0% vs 92.1% (HR 0.75, P = 0.21) Grade ≥ 3 AEs: 74.6% vs 67.8%
[45]		413	FL (rituximab refractory) O + Benda vs Benda	3	PFS: NR vs 14.9 mo (HR 0.55, P = 0.0001) OS: ND Grade ≥ 3 AEs: Neutropenia 33% vs 26%; Infusion reactions 11% vs 6%
Tafasitamab[47]	CD19	92	DLBCL R/RT + Lenalidomide	2	ORR: 43% CR: 18% PFS: 12.1 mo Grade ≥ 3 AEs: Neutropenia 48%, Thrombocytopenia 17%, Febrile neutropenia 12%
Magrolimab[52]	CD47	22	R/R DLBCL or FL M + R	1b	DLBCL ORR/CR: 40%/33% FL ORR/CR: 71%/43% AEs: Anemia, Infusion reactions
Mogamulizumab[53]	CCR4	372	CTCL R/R Mo vs Vorinostat	3	PFS: 7.7 mo vs 3.1 mo (HR 0.53, P < 0.0001) Grade ≥ 3 AEs: Mo: pyrexia 4%, cellulitis 3%; V: cellulitis 3%, PE 3%, sepsis 3%

AE: Adverse event; Benda: Bendamustin; CCR4: C chemokine receptor 4; Chemo: Chemotherapy; CIRS: Cumulative illness rating scale; Clb: Chlorambucil; CLL: Chronic lymphocytic leukemia; CR: Complete response; CTCL: Cutaneous T-cell lymphomas; DLBCL: Diffuse large B-cell lymphoma; FL: Follicular lymphoma; M: Macrolimab; Мо: Mogalizumab; NR: Not reached; O: Obinutuzumab; ORR: Objective response rate; OS: Overall survival; PE: Pulmonary embolism. PFS: Progression-free survival; R: Rituximab; R/R: Relapsed/refractory; V: Vorinostat.